Olaparib In Metastatic Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Olaparib In Metastatic Breast Cancer	Fanconi anemia complementation group D1, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder	Active, not recruiting	Phase 2	2026-01-05		NCT03344965

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AstraZeneca	806
Beth Israel Deaconess Medical Center	161
Dana-Farber Cancer Institute	324
Johns Hopkins University	579

20 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beth Israel Deaconess Medical Center	Boston	United States	45
Brigham and Women's Hospital	Boston	United States	511
Dana-Farber Cancer Institute	Boston	United States	626
Duke University	Durham	United States	45
Indiana University	Indianapolis	United States	160
Johns Hopkins University	Baltimore	United States	49
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Memorial Sloan Kettering Cancer Center Basking Ridge	Basking Ridge	United States	8
Memorial Sloan Kettering Cancer Center Bergen	Montvale	United States	2
Memorial Sloan Kettering Cancer Center Commack	Commack	United States	4
Memorial Sloan Kettering Cancer Center Monmouth	Middletown	United States	2
Memorial Sloan Kettering Cancer Center Nassau	Uniondale	United States	3
Memorial Sloan Kettering Cancer Center Westchester	East White Plains	United States	1
University of Alabama at Birmingham	Birmingham	United States	247
University of California, San Francisco	San Francisco	United States	294
University of Chicago	Chicago	United States	312
University of Pennsylvania	Philadelphia	United States	507
University of Pittsburgh	Pittsburgh	United States	38
University of Washington Fred Hutchinson Cancer Care	Seattle	United States	3
UPMC Hillman Cancer Center - Erie	Erie	United States	1

Clinical trials